Risk Stratification Value of Biomarkers in Patients With Ventricular Arrhythmias

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Jul 20, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how certain biological markers in the body can help doctors better understand and treat patients with ventricular arrhythmias, which are irregular heartbeats that can lead to serious health issues. The study will focus on measuring immune system status and the makeup of gut bacteria in patients before and after a procedure called radiofrequency ablation, which is used to correct these heart rhythm problems. The goal is to develop personalized treatment plans and improve prediction models for patients' health after treatment.

To be eligible for this trial, participants need to be between 18 and 80 years old and have experienced specific heart issues, such as ventricular premature beats or tachycardia, as confirmed by an electrocardiogram (a test that records the heart's electrical activity). However, the trial excludes individuals with certain health conditions, such as autoimmune diseases or those who have recently taken medications affecting the immune system. Participants can expect to undergo tests and evaluations that will help researchers learn more about how these biological markers relate to their heart condition, contributing to better care for future patients. It's important to note that the trial is not yet recruiting participants, so there will be a wait before enrollment begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with ventricular premature beats, ventricular tachycardia, or ventricular fibrillation detected by regular surface twelve-lead electrocardiogram or Holter.
• Exclusion Criteria:
• • Age \<18 or \>80 years old;
• • Patients with autoimmune diseases or immune deficiencies, or those who have used immunosuppressive or immune modulating agents in the past 3 months;
• • Platelet count \<100×10\^9/L or functional platelet defects;
• • Congenital or acquired coagulation or bleeding disorders;
• • Patients with a history of organ transplantation or are preparing to receive organ transplantation;
• • Unwilling to sign an informed consent or cooperate with the examination.